$62.90
0.19% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Stock price

$62.90
+6.11 10.76% 1M
+7.66 13.87% 6M
+6.92 12.36% YTD
+18.53 41.76% 1Y
+42.38 206.53% 5Y
+32.90 109.67% 10Y
+32.90 109.67% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.12 0.19%
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Key metrics

Market capitalization $4.00b
Enterprise Value $3.80b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 23.32
P/S ratio (TTM) P/S ratio 24.58
P/B ratio (TTM) P/B ratio 24.49
Revenue growth (TTM) Revenue growth 77.14%
Revenue (TTM) Revenue $162.83m
EBIT (operating result TTM) EBIT $-312.51m
Free Cash Flow (TTM) Free Cash Flow $-113.49m
Cash position $314.49m
EPS (TTM) EPS $-5.00
P/E forward negative
P/S forward 22.80
EV/Sales forward 21.64
Short interest 9.75%
Show more

Is Rhythm Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Rhythm Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

12x Buy
100%

Analyst Opinions

12 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast:

Buy
100%

Financial data from Rhythm Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
163 163
77% 77%
100%
- Direct Costs 17 17
59% 59%
10%
146 146
79% 79%
90%
- Selling and Administrative Expenses 183 183
44% 44%
113%
- Research and Development Expense 275 275
22% 22%
169%
-311 -311
15% 15%
-191%
- Depreciation and Amortization 1.54 1.54
9% 9%
1%
EBIT (Operating Income) EBIT -313 -313
15% 15%
-192%
Net Profit -315 -315
15% 15%
-194%

In millions USD.

Don't miss a Thing! We will send you all news about Rhythm Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Rhythm Pharmaceuticals, Inc. Stock News

Positive
Investors Business Daily
16 days ago
Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.
Neutral
GlobeNewsWire
about one month ago
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric Endocrinology and the European Society of Endocrinology (ESPE-ESE); 32 nd annual European Congress on Obesity (ECO); and the 2025 annual meeting of the Pediatric Endocrine Society (PES 2025) -- BOSTO...
Neutral
Seeking Alpha
about one month ago
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
More Rhythm Pharmaceuticals, Inc. News

Company Profile

Rhythm Pharmaceuticals, Inc. engages in developing and commercializing peptide therapeutics for the treatment of gastrointestinal diseases and genetic deficiencies. It focuses on the treatment for Prader-Willi Syndrome and Pro-Opiomelanocortin deficiency obesity. Its product candidate includes setmelanotide, an MC4R agonist designed to restore impaired MC4R pathway function caused by genetic variants that occur upstream of the MC4R. The company was founded by Bart Henderson in November 2008 and is headquartered in Boston, MA.

Head office United States
CEO David Meeker
Employees 283
Founded 2008
Website rhythmtx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today